Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years

被引:7
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Zhan, Xuemei [4 ]
Zhang, Yi [5 ]
Xu, Yan [6 ]
Li, Weili [2 ]
Lang, Jinghe [2 ,7 ]
Liu, Ping [2 ]
Chen, Chunlin [1 ,2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang, Peoples R China
[4] SEN Univ, Affiliated Jiangmen Hosp SUN YAT, Dept Obstet & Gynecol, Jiangmen, Peoples R China
[5] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China
[6] Pan Yu Cent Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
cervical cancer; disease-free survival; intermediate-risk pathological factor; oncological outcome; overall survival; postoperative adjuvant therapy; RADICAL HYSTERECTOMY; PELVIC IRRADIATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; IB; RADIOTHERAPY; CISPLATIN; METASTASIS;
D O I
10.1111/jog.15632
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
引用
收藏
页码:1579 / 1591
页数:13
相关论文
共 50 条
  • [21] Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study
    Ragab, Omar M.
    Mehta, Shahil
    Nusbaum, David J.
    Shimada, Muneaki
    Brunette, Laurie L.
    Roman, Lynda D.
    Matsuo, Koji
    BRACHYTHERAPY, 2022, 21 (02) : 141 - 150
  • [22] Impact of postoperative intravaginal brachytherapy on survival for patients with intermediate-risk cervical cancer at National Cancer Institute (NCI), Egypt
    Mahmoud, Mohamed
    Abdelgeleel, Shaimaa
    Mahmoud, Ahmed M.
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2018, 17 (03) : 332 - 336
  • [23] Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer A Pilot Study
    Aloisi, Alessia
    Plotti, Francesco
    Scaletta, Giuseppe
    Capriglione, Stella
    Laraud, Federica
    Miranda, Andrea
    Montera, Roberto
    Nardone, Carlo De Cicco
    Terranova, Corrado
    Angioli, Roberto
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (08) : 1418 - 1423
  • [24] Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer
    Jin, Meng
    Hou, Xiaorong
    Sun, Xiansun
    Zhang, Yuelun
    Hu, Ke
    Zhang, Fuquan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (08) : 1264 - 1270
  • [25] Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study
    Mahmoud, Omar
    Hathout, Lara
    Shaaban, Sherif G.
    Elshaikh, Mohamed A.
    Beriwal, Sushil
    Small, William, Jr.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 539 - 544
  • [26] The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer
    Kleppe, Marjolein
    van der Aa, Maaike A.
    Van Gorp, Toon
    Slangen, Brigitte F. M.
    Kruitwagen, Roy F. P. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 66 : 83 - 90
  • [27] Non-squamous histology but not adjuvant therapy affects survival in stage IB-IIA cervical cancer patients with intermediate risk following radical hysterectomy
    Wang, Ying-Wen
    Lin, Hao
    Fu, Hung-Chun
    Chien, Chan-Chao Chang
    Ou, Yu-Che
    Lee, Pei-Hang
    Huang, Chao-Cheng
    Wu, Chen-Hsuan
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (06) : 1205 - 1212
  • [28] Progressive Skeletal Muscle Loss After Surgery and Adjuvant Radiotherapy Impact Survival Outcomes in Patients With Early Stage Cervical Cancer
    Lee, Jie
    Lin, Jhen-Bin
    Chen, Tze-Chien
    Jan, Ya-Ting
    Sun, Fang-Ju
    Chen, Yu-Jen
    Wu, Meng-Hao
    FRONTIERS IN NUTRITION, 2022, 8
  • [29] Survival of Danish Patients With Endometrial Cancer in the Intermediate-Risk Group Not Given Postoperative Radiotherapy The Danish Endometrial Cancer Study (DEMCA)
    Bertelsen, Kamma
    Ortoft, Gitte
    Hansen, Estrid Staehr
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (07) : 1191 - 1199
  • [30] Postoperative management of FIGO 2018 stage IIA1 cervical squamous cell carcinoma with only one intermediate-risk factor: Is radiotherapy needed?
    Liu, Yunlu
    He, Junshen
    Liu, Ping
    Chen, Chunlin
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2023, 162 (03) : 1098 - 1105